Evidence map›Paper›PMID 25206429›Full record

ArticleNeural regeneration research2013

Protective effect of oxysophoridine on cerebral ischemia/reperfusion injury in mice.

Hongbo Wang, Yuxiang Li, Ning Jiang, Xiaoping Chen, Yi Zhang, Kuai Zhang, Tengfei Wang, Yinju Hao, Lin Ma, Chengjun Zhao and 3 more

Open access · greenAbstract read
In one paragraph

Article in Neural regeneration research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Inhibitory Effect ofMolecules (Basel, Switzerland) · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Hongbo WangDepartment of Pharmacology, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Yuxiang LiCollege of Nursing, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China ; Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, China.
Ning JiangShanghai Pudong New Area Gongli Hospital, Shanghai 200135, China.
Xiaoping ChenShanghai Pudong New Area Gongli Hospital, Shanghai 200135, China.
Yi ZhangShanghai Pudong New Area Gongli Hospital, Shanghai 200135, China.
Kuai ZhangDepartment of Pharmacology, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Tengfei WangDepartment of Pharmacology, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Yinju HaoDepartment of Pharmacology, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Lin MaNingxia Key Laboratory of Craniocerebral Diseases of Ningxia Hui Autonomous Region, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Chengjun ZhaoSchool of Basic Medical Sciences, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Yanrong WangKey Laboratory of Reproduction and Genetics of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Tao SunNingxia Key Laboratory of Craniocerebral Diseases of Ningxia Hui Autonomous Region, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Jianqiang YuDepartment of Pharmacology, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China ; Collaborative Innovation Center of Ningxia Hui Autonomous Region for Medicines, Yinchuan 750004, Ningxia Hui Autonomous Region, China.
Second Military Medical University · CNShanghai Pudong New Area Gongli Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxysophoridine, a new alkaloid extracted from Sophora alopecuroides L., has been shown to have a protective effect against ischemic brain damage. In this study, a focal cerebral ischemia/reperfusion injury model was established using middle cerebral artery occlusion in mice. Both 62.5, 125, and 250 mg/kg oxysophoridine, via intraperitoneal injection, and 6 mg/kg nimodipine, via intragastric administration, were administered daily for 7 days before modeling. After 24 hours of reperfusion, mice were tested for neurological deficit, cerebral infarct size was assessed and brain tissue was collected. Results showed that oxysophoridine at 125, 250 mg/kg and 6 mg/kg nimodipine could reduce neurological deficit scores, cerebral infarct size and brain water content in mice. These results provided evidence that oxysophoridine plays a protective role in cerebral ischemia/reperfusion injury. In addition, oxysophoridine at 62.5, 125, and 250 mg/kg and 6 mg/kg nimodipine increased adenosine-triphosphate content, and decreased malondialdehyde and nitric oxide content. These compounds enhanced the activities of glutathione-peroxidase, superoxide dismutase, catalase, and lactate dehydrogenase, and decreased the activity of nitric oxide synthase. Protein and mRNA expression levels of N-methyl-D-aspartate receptor subunit NR1 were markedly inhibited in the presence of 250 mg/kg oxysophoridine and 6 mg/kg nimodipine. Our experimental findings indicated that oxysophoridine has a neuroprotective effect against cerebral ischemia/reperfusion injury in mice, and that the effect may be due to its ability to inhibit oxidative stress and expression of the N-methyl-D-aspartate receptor subunit NR1.

Indexed as

brain injurygrants-supported paperischemia/reperfusion injuryneural regenerationneuroprotectionneuroregenerationN-methyl-D-aspartate receptoroxidative stressoxysophoridinetraditional Chinese medicine

Identifiers

PMID25206429
PMCPMC4107767
OpenAlexW94096929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.